Market Overview:
The global HDAC inhibitor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The HDAC inhibitors are used for the treatment of various cancers, such as pancreatic cancer, leukemia, and lymphoma. The Belinostat is the most commonly used HDAC inhibitor for the treatment of PECL (peripheral T-cell lymphoma). However, due to its high cost and side effects such as nausea and vomiting, Romidepsin is becoming more popular among patients. Chidamide is also being increasingly used in Asia Pacific owing to its better safety profile compared with other HDAC inhibitors.
 Inhibitor Industry Outlook.svg)
Product Definition:
A histone deacetylase inhibitor (HDACi) is a type of drug that blocks the function of histone deacetylases. HDACs are enzymes that remove acetyl groups from proteins, including histones. Histones play a role in gene regulation, and their modification by acetylation can influence the expression of genes. HDAC inhibitors can block the removal of acetyl groups from histones, which results in an "open" chromatin structure and increased gene transcription. HDAC inhibitors are used as cancer treatments and to promote nerve regeneration.
Belinostat:
The global Belinostat, it's usage and growth factor in HDAC (histone deacetylase) inhibitor market size was valued at USD 1.8 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The rising prevalence of cancer worldwide coupled with increasing awareness regarding early diagnosis & treatment is one of the key factors anticipated to boost demand for belinostat during the forecast period.
Romidepsin:
Romidepsin is a naturally occurring compound isolated from the fungus Romalea michelii. It was first discovered and characterized in 1980, by researchers at the National Institute of Health (NIH) as an intermediate compound for the synthesis of antibiotics. More recently, it has been identified as an HDAC inhibitor with potential clinical applications in treatment of cancer and other diseases related to aging such as neurodegenerative disorders and inflammatory conditions.
Application Insights:
PECL treatment was the largest revenue-generating segment in 2017. PECL is a type of blood cancer that affects mostly white males aged 65 years and above. HDAC inhibitor is used for the treatment of PECL as it deactivates an enzyme called Histone Deacetylase, which plays a major role in causing different types of cancers including liver, breast and kidney among others.
The other application segment includes anti-cancer drugs for other malignant diseases such as lung, pancreatic & biliary system cancer, melanoma skin cancer etc. These are used either alone or in combination with chemotherapy drugs for treating these diseases based on their varying stages and characteristics. The use of HDAC inhibitors has increased significantly over the past few years owing to its ability to treat various types of cancers at different stages thereby increasing market penetration across regions since 2016 (post approval by respective regulatory authorities).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high research activity and availability of effective treatment methods for different cancers. In addition, increasing number of clinical trials conducted by major companies is also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising incidence rates of cancer in this region coupled with growing awareness about available treatment options among patients and physicians. Rising disposable income levels are also likely boost regional demand for HDAC inhibitors over the next eight years (2018-2030). Moreover, increasing healthcare expenditure by governments as well as private sectors in order to improve healthcare facilities is further expected propel market development during this period.
Growth Factors:
- Increasing research and development activities for novel HDAC inhibitors for the treatment of various diseases.
- Growing demand for targeted therapies and personalized medicines.
- Rising prevalence of cancer, autoimmune disorders, and other chronic diseases worldwide.
- increasing number of clinical trials being conducted on HDAC inhibitors for the treatment of various indications
Scope Of The Report
Report Attributes
Report Details
Report Title
HDAC (histone deacetylase) Inhibitor Market Research Report
By Type
Belinostat, Romidepsin, Chidamide
By Application
PECL Treatment, Other Cancers Treatment
By Companies
Shenzhen Chipscreen, Spectrum Pharmaceuticals, Celegne
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global HDAC (histone deacetylase) Inhibitor Market Report Segments:
The global HDAC (histone deacetylase) Inhibitor market is segmented on the basis of:
Types
Belinostat, Romidepsin, Chidamide
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
PECL Treatment, Other Cancers Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Shenzhen Chipscreen
- Spectrum Pharmaceuticals
- Celegne
 Inhibitor Market Overview.svg)
Highlights of The HDAC (histone deacetylase) Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Belinostat
- Romidepsin
- Chidamide
- By Application:
- PECL Treatment
- Other Cancers Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the HDAC (histone deacetylase) Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitor Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
HDAC inhibitors are drugs that block the activity of histone deacetylases (HDACs). HDAC inhibitors can be used to treat a variety of diseases, including cancer.
Some of the major players in the hdac (histone deacetylase) inhibitor market are Shenzhen Chipscreen, Spectrum Pharmaceuticals, Celegne.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 HDAC (histone deacetylase) Inhibitor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 HDAC (histone deacetylase) Inhibitor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 HDAC (histone deacetylase) Inhibitor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the HDAC (histone deacetylase) Inhibitor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global HDAC (histone deacetylase) Inhibitor Market Size & Forecast, 2018-2028
4.5.1 HDAC (histone deacetylase) Inhibitor Market Size and Y-o-Y Growth
4.5.2 HDAC (histone deacetylase) Inhibitor Market Absolute $ Opportunity
Chapter 5 Global HDAC (histone deacetylase) Inhibitor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 HDAC (histone deacetylase) Inhibitor Market Size Forecast by Type
5.2.1 Belinostat
5.2.2 Romidepsin
5.2.3 Chidamide
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global HDAC (histone deacetylase) Inhibitor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 HDAC (histone deacetylase) Inhibitor Market Size Forecast by Applications
6.2.1 PECL Treatment
6.2.2 Other Cancers Treatment
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global HDAC (histone deacetylase) Inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 HDAC (histone deacetylase) Inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America HDAC (histone deacetylase) Inhibitor Analysis and Forecast
9.1 Introduction
9.2 North America HDAC (histone deacetylase) Inhibitor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America HDAC (histone deacetylase) Inhibitor Market Size Forecast by Type
9.6.1 Belinostat
9.6.2 Romidepsin
9.6.3 Chidamide
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America HDAC (histone deacetylase) Inhibitor Market Size Forecast by Applications
9.10.1 PECL Treatment
9.10.2 Other Cancers Treatment
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe HDAC (histone deacetylase) Inhibitor Analysis and Forecast
10.1 Introduction
10.2 Europe HDAC (histone deacetylase) Inhibitor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe HDAC (histone deacetylase) Inhibitor Market Size Forecast by Type
10.6.1 Belinostat
10.6.2 Romidepsin
10.6.3 Chidamide
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe HDAC (histone deacetylase) Inhibitor Market Size Forecast by Applications
10.10.1 PECL Treatment
10.10.2 Other Cancers Treatment
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific HDAC (histone deacetylase) Inhibitor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific HDAC (histone deacetylase) Inhibitor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific HDAC (histone deacetylase) Inhibitor Market Size Forecast by Type
11.6.1 Belinostat
11.6.2 Romidepsin
11.6.3 Chidamide
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific HDAC (histone deacetylase) Inhibitor Market Size Forecast by Applications
11.10.1 PECL Treatment
11.10.2 Other Cancers Treatment
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America HDAC (histone deacetylase) Inhibitor Analysis and Forecast
12.1 Introduction
12.2 Latin America HDAC (histone deacetylase) Inhibitor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America HDAC (histone deacetylase) Inhibitor Market Size Forecast by Type
12.6.1 Belinostat
12.6.2 Romidepsin
12.6.3 Chidamide
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America HDAC (histone deacetylase) Inhibitor Market Size Forecast by Applications
12.10.1 PECL Treatment
12.10.2 Other Cancers Treatment
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) HDAC (histone deacetylase) Inhibitor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) HDAC (histone deacetylase) Inhibitor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) HDAC (histone deacetylase) Inhibitor Market Size Forecast by Type
13.6.1 Belinostat
13.6.2 Romidepsin
13.6.3 Chidamide
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) HDAC (histone deacetylase) Inhibitor Market Size Forecast by Applications
13.10.1 PECL Treatment
13.10.2 Other Cancers Treatment
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 HDAC (histone deacetylase) Inhibitor Market: Competitive Dashboard
14.2 Global HDAC (histone deacetylase) Inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Shenzhen Chipscreen
14.3.2 Spectrum Pharmaceuticals
14.3.3 Celegne
